236 related articles for article (PubMed ID: 38443664)
1. Rational design of a single-component mRNA vaccine against orthopoxvirus and SARS-CoV-2.
Yang Y; Zhao X; Li Y; Zai X; Wang X; Zhang Y; Wang X; Lv P; Zhang J; Hou L; Xu J; Chen W
Sci China Life Sci; 2024 Jun; 67(6):1311-1313. PubMed ID: 38443664
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
Connors M; Graham BS; Lane HC; Fauci AS
Ann Intern Med; 2021 May; 174(5):687-690. PubMed ID: 33460347
[TBL] [Abstract][Full Text] [Related]
3. Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design.
Pickup DJ
Expert Rev Vaccines; 2007 Feb; 6(1):87-95. PubMed ID: 17280481
[TBL] [Abstract][Full Text] [Related]
4. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
[No Abstract] [Full Text] [Related]
5. Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV: Erratum.
AIDS; 2024 Jul; 38(8):1279. PubMed ID: 38814720
[No Abstract] [Full Text] [Related]
6. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
[No Abstract] [Full Text] [Related]
7. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
[TBL] [Abstract][Full Text] [Related]
8. Reflections on SARS-CoV-2 new strain contagiousness and its prevention with mRNA vaccines.
García-Vigil JL; García-Alvarez JL
Gac Med Mex; 2021; 157(3):318. PubMed ID: 34667321
[No Abstract] [Full Text] [Related]
9. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
10. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
Front Immunol; 2022; 13():811802. PubMed ID: 35250985
[TBL] [Abstract][Full Text] [Related]
11. Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization.
Niemiałtowski MG; Toka FN; Malicka E; Gieryńska ; Spohr de Faundez I; Schollenberger A
Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):373-8. PubMed ID: 9017154
[TBL] [Abstract][Full Text] [Related]
12. The overlooked superpower of mRNA vaccines.
Wadman M
Science; 2021 Jul; 373(6554):479. PubMed ID: 34326217
[No Abstract] [Full Text] [Related]
13. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 evolution and vaccines: cause for concern?
Williams TC; Burgers WA
Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
[No Abstract] [Full Text] [Related]
15. Neutralizing Activity of BNT162b2-Elicited Serum.
Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
[No Abstract] [Full Text] [Related]
16. Messenger RNA vaccines against SARS-CoV-2.
Topol EJ
Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
[TBL] [Abstract][Full Text] [Related]
17. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
[TBL] [Abstract][Full Text] [Related]
18. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
19. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.
Gebre MS; Rauch S; Roth N; Yu J; Chandrashekar A; Mercado NB; He X; Liu J; McMahan K; Martinot A; Martinez DR; Giffin V; Hope D; Patel S; Sellers D; Sanborn O; Barrett J; Liu X; Cole AC; Pessaint L; Valentin D; Flinchbaugh Z; Yalley-Ogunro J; Muench J; Brown R; Cook A; Teow E; Andersen H; Lewis MG; Boon ACM; Baric RS; Mueller SO; Petsch B; Barouch DH
Nature; 2022 Jan; 601(7893):410-414. PubMed ID: 34794169
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
Bloomfield M; Parackova Z; Hanzlikova J; Lastovicka J; Sediva A
J Clin Immunol; 2022 Feb; 42(2):266-269. PubMed ID: 34718945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
